Home » Cancer Treatment Options » Complementary therapies


Complementary cancer therapies comprise a wide range of therapies, products, and strategies that are used in addition to standard and alternative cancer treatments.

Studies have shown that complementary therapies have a number of beneficial effects. They can be used to reduce treatment side-effects and pain, improve treatment outcomes, and prolong survival.

Here are details of the main groups of Complementary Therapies

Therapies to Prolong Survival

Therapies and products shown in human studies to prolong survival.
Go to Cancer Survival Tips

Therapies to Reduce Side-effects

Ways to reduce treatment side-effects and pain.
Go to Reduce cancer treatment side-effects

Therapies to Boost Immunity

A wide range of ways to strengthen your immunity.
Go to Boost Your Immune System

Therapies to promote Emotional Healing

An essential component of any cancer recovery plan.
Go to Emotional and Spiritual healing

Therapies to address Cancer Stem Cells

Cancer Stem Cells cause most metastases.
Go to Cancer Stem Cells and Senescent Cancer Cells

Therapies using Herbs, Spices, and Supplements

Selective herbs have anti-cancer properties.
Go to Herbs, Spices, and Supplements

Other Complementary therapies

Ann Wigmore – Living Foods Lifestyle

BioMagnetic Pair Therapy

Broccoli Sprout Extract

Dong quai (Angelica sinensis)

Dr. Matthias Rath Cellular Solution

Hands-on Healing

Issels Treatment

Myers Cocktail

Tibetan Medicine

Therapeutic Touch

Tai Chi


Pulsed Electromagnetic Field Therapy


Tigilanol tiglate (EBC-46)

EBC-46, also known as “N-butyl-2-cyanoacrylate,” is a compound that has been shown to be effective in destroying tumors in preclinical studies. This compound works by penetrating the tumor and releasing a toxic substance that kills the cancer cells – Blushwood Health (suppliers of Blushwood Berry Seed Extract)

According to this study:
Tigilanol tiglate (EBC-46) is currently in development for the local treatment of a broad range of tumors. In this first-in-human Phase I study, IT [intratumoral] administration of tigilanol tiglate was generally well tolerated… and signals of clinical efficacy were identified across nine tumor types. Four patients- two with metastatic melanoma, one with atypical fibroxanthoma [an uncommon, skin malignancy] and one with angiosarcoma [a rare type of cancer that forms in the lining of the blood vessels and lymph vessels] – achieved complete response in the treated lesions…

See also Risk of Recurrence

Cancer Treatment Options

Page updated 2023

Please share this page to help others